CClinicalTrials.gg
RecruitingNCT06119802Updated Nov 7, 2023

Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation

An observational study in Atrial Fibrillation and Hyperuricemia, sponsored by Yinglong Hou. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Yinglong Hou · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
10,000
Ages
18 Years to 90 Years
Sex
All
01

Study summary

To clarify the predictive effects of uric acid and superoxide dismutase as biomarkers of oxidative stress on atrial fibrillation, and to provide greater value for the diagnosis and prediction of atrial fibrillation. It provides a new idea for the prevention and treatment of atrial fibrillation.

Read the detailed description

In recent years, a growing number of reports have shown the importance of oxidative stress in the pathophysiological mechanism of AF. During oxidative stress, there is an imbalance between the production of pro-oxidant reactive species and the antioxidant defenses of the cell, and excessive oxidation leads to oxidative damage and cell death. Redox processes can lead to atrial fibrosis and cardiac remodeling , suggesting that strategies to address myocardial oxidative stress may constitute a reasonable approach for the treatment of AF. However, few studies have reported the relationship between comprehensive oxidative stress-related biomarkers and AF. The purpose of this study was to illuminate the relationship of several blood markers of oxidative stress with AF and to provide new clues for the prevention and treatment of AF.

02

Conditions studied

  • Atrial Fibrillation
  • Hyperuricemia

Keywords

  • hyperuricemia
  • atrial fibrillation
03

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This retrospective study enrolled all hospitalized patients from January 2018 to December 2020 at the Department of Cardiology in The First Affiliated Hospital of Shandong First Medical University.

Eligibility criteria

Inclusion Criteria: This retrospective study enrolled all hospitalized patients from January 2018 to December 2020 at the Department of Cardiology in The First Affiliated Hospital of Shandong First Medical University. The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF.

Exclusion Criteria:

  1. acute heart failure and acute myocardial infarction;
  2. severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate \<30 ml/ (min*1.73 m2));
  3. malignant tumors;
  4. missing data of laboratory indicators at baseline.
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Atrial Fibrillation cohort

    The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF. The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate \<30 ml/ (min\*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.

    Diagnostic Test: atrial fibrillation

  • Non-atrial Fibrillation cohort

    Patients attending the Department of Cardiology to rule out atrial fibrillation.The exclusion criteria were as follows: (1) acute heart failure and acute myocardial infarction; (2) severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate \<30 ml/ (min\*1.73 m2)); (3) malignant tumors; and (4) missing data of laboratory indicators at baseline.

Interventions

  • Diagnostic testatrial fibrillation

    ECG of atrial fibrillation last more than 30 seconds.

05

What researchers measure

Primary outcomes

  1. Uric acid/SOD ratio is associated with atrial fibrillation

    Uric acid/SOD ratio is associated with atrial fibrillation

    Time frame: 3 years

06

Study locations

1 of 1 sites recruiting
  • Shandong provincal Qianfoshan hospital
    Jinan, Shandong 250014, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06119802
Lead sponsor
Yinglong Hou
Responsible party
Yinglong Hou (professor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Nov 7, 2023
Start date
Jan 1, 2022
Primary completion
Oct 31, 2023 (estimated)
Completion
Apr 30, 2024 (estimated)
Last update
Nov 7, 2023

Study contacts

Yinglong Hou, PhD
Contact
yujiao61@163.com
13791120810
Hui Tian, PhD
study chair · Qianfoshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion